newsfilter
← Latest News
GlobeNewswire·

HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer

Designated as one of the Top 150 abstracts submitted for the 41st Annual Meeting of the Society for Immunotherapy of Cancer HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab (Keytruda®) based